These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22212561)

  • 1. Effect of pregnancy on immunological and virological outcomes of women on ART: a prospective cohort study in rural Uganda, 2004-2009.
    Mayanja BN; Shafer LA; Van der Paal L; Kyakuwa N; Ndembi N; Hughes P; Maher D; Grosskurth H
    Trop Med Int Health; 2012 Mar; 17(3):343-52. PubMed ID: 22212561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12-month cohort study in urban South Africa and rural Uganda.
    Matthews LT; Orrell C; Bwana MB; Tsai AC; Psaros C; Asiimwe S; Amanyire G; Musinguzi N; Bell K; Bangsberg DR; Haberer JE;
    J Int AIDS Soc; 2020 Aug; 23(8):e25586. PubMed ID: 32820622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.
    Langwenya N; Phillips TK; Brittain K; Zerbe A; Abrams EJ; Myer L
    J Int AIDS Soc; 2018 Jun; 21(6):e25133. PubMed ID: 29939483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
    Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.
    Onoya D; Sineke T; Brennan AT; Long L; Fox MP
    AIDS; 2017 Jul; 31(11):1593-1602. PubMed ID: 28463877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.
    Matthews LT; Kaida A; Kanters S; Byakwagamd H; Mocello AR; Muzoora C; Kembabazi A; Haberer JE; Martin JN; Bangsberg DR; Hunt PW
    AIDS; 2013 Oct; 27 Suppl 1(0 1):S105-12. PubMed ID: 24088676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1-infected women.
    Heffron R; Donnell D; Kiarie J; Rees H; Ngure K; Mugo N; Were E; Celum C; Baeten JM;
    J Acquir Immune Defic Syndr; 2014 Feb; 65(2):231-6. PubMed ID: 24442226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
    Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
    Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women.
    Giuliano M; Pirillo MF; Liotta G; Andreotti M; Jere H; Sagno JB; Ciccacci F; Amici R; Marazzi MC; Vella S; Palombi L; Mancinelli S
    J Clin Virol; 2017 Nov; 96():17-19. PubMed ID: 28918126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating Option B+ in Uganda: an observational study nested within a randomized controlled trial.
    Gabagaya G; Rukundo G; Amone A; Wavamunno P; Namale-Matovu J; Lubega I; Nakabiito C; Namukwaya Z; Nolan M; Malamba SS; King R; Homsy J; Fowler MG; Musoke P
    BMC Infect Dis; 2021 Sep; 21(1):907. PubMed ID: 34481464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda.
    Koss CA; Natureeba P; Kwarisiima D; Ogena M; Clark TD; Olwoch P; Cohan D; Okiring J; Charlebois ED; Kamya MR; Havlir DV
    J Acquir Immune Defic Syndr; 2017 Mar; 74(3):279-284. PubMed ID: 27828878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pregnancy on HIV disease progression and survival among women in rural Uganda.
    Lieve Vd; Shafer LA; Mayanja BN; Whitworth JA; Grosskurth H
    Trop Med Int Health; 2007 Aug; 12(8):920-8. PubMed ID: 17697086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does pregnancy affect the early response to cART?
    Rachas A; Warszawski J; Le Chenadec J; Legeai C; Teglas JP; Goujard C; Rouzioux C; Mandelbrot L; Tubiana R; Meyer L
    AIDS; 2013 Jan; 27(3):357-67. PubMed ID: 23079802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.
    Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS;
    AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy.
    Mnyani CN; McIntyre JA; Myer L
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):260-4. PubMed ID: 22487589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study.
    Lyatuu GW; Mwashemele SZ; Urrio R; Naburi H; Kashmir N; Machumi L; Kibao A; Sellah Z; Ulenga N; Orsini N; Biberfeld G; Kilewo C; Ekström AM
    Lancet HIV; 2021 May; 8(5):e256-e265. PubMed ID: 33581776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
    Carter RJ; Dugan K; El-Sadr WM; Myer L; Otieno J; Pungpapong N; Toro PL; Abrams EJ;
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):404-10. PubMed ID: 20595905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods.
    Matthews LT; Ribaudo HB; Kaida A; Bennett K; Musinguzi N; Siedner MJ; Kabakyenga J; Hunt PW; Martin JN; Boum Y; Haberer JE; Bangsberg DR
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):399-406. PubMed ID: 26495883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.